CompletedNot Applicable

Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples

Austria, Germany87 participantsStarted 2007-04

Plain-language summary

Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain reaction (PCR) and Aspergillus galactomannan (GM) ELISA is unclear, and the BAL cutoff for GM has not been clearly defined yet. Using a validated nested PCR assay and a GM ELISA, we prospectively examine BAL samples from hematological patients at high risk of PA.

Who can participate

Age range5 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- hematological patients with lung infiltrates at high risk for invasive aspergillosis Exclusion Criteria: \- patients without informed consent

What they're measuring

Clinical significance of biomarker based diagnostic investigation in suspected invasive aspergillosis

Timeframe: up to 18 months

Trial details

NCT IDNCT01430663

SponsorHeidelberg University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-02

View on ClinicalTrials.gov More Invasive Aspergillosis trials